Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Eliot N. Mostow MD, MPH Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · January 25, 2017

Novel Multivariant ELISA Effective for the Diagnosis of Autoimmune Blistering Diseases

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Diya Mutasim MD

Journal of the American Academy of Dermatology

Prospective Studies on the Routine Use of a Novel Multivariant Enzyme-Linked Immunosorbent Assay for the Diagnosis of Autoimmune Bullous Diseases

J Am Acad Dermatol 2016 Dec 28;[EPub Ahead of Print], N van Beek, C Dähnrich, N Johannsen, S Lemcke, S Goletz, F Hübner, G Di Zenzo, M Dmochowski, K Drenovska, S Geller, M Horn, C Kowalewski, L Medenica, DF Murrell, A Patsatsi, S Uzun, S Vassileva, D Zillikens, W Schlumberger, E Schmidt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Novel Multivariant ELISA Effective for the Diagnosis of Autoimmune Blistering Diseases

Additional Info

Prospective Studies on the Routine Use of a Novel Multivariant Enzyme-Linked Immunosorbent Assay for the Diagnosis of Autoimmune Bullous Diseases

Further Reading

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Efficacy of Treatment With Bimekizumab in Patients With Hidradenitis Suppurativa

Efficacy and Safety of Treatment With Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Recently Updated